Aspirin Shows No Survival Benefit in Colorectal Cancer Treatment
Exploring the Role of Aspirin in Post-Treatment Outcomes for Colorectal Cancer Patients
Topline
The ASCOLT trial found that aspirin, at a daily dose of 200 mg, did not significantly improve disease-free survival (DFS) or overall survival (OS) in patients with colorectal cancer following standard adjuvant therapy.
Study Details
Colorectal cancer (CRC) remains a leading cause of cancer-related deaths globally. Aspirin, a well-known anti-inflamm…
Keep reading with a 7-day free trial
Subscribe to Just Healthcare to keep reading this post and get 7 days of free access to the full post archives.